AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

The trial will see healthy volunteers infected with dengue to test the impact of AbViro’s monoclonal antibody therapy.